Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Gains from Investment Securities: 2012-2024

Historic Gains from Investment Securities for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Dec 2024 value amounting to $6.7 million.

  • Amphastar Pharmaceuticals' Gains from Investment Securities rose 11.46% to $6.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.9 million, marking a year-over-year decrease of 86.07%. This contributed to the annual value of $6.7 million for FY2024, which is 14.26% down from last year.
  • Amphastar Pharmaceuticals' Gains from Investment Securities amounted to $6.7 million in FY2024, which was down 14.26% from $7.8 million recorded in FY2023.
  • In the past 5 years, Amphastar Pharmaceuticals' Gains from Investment Securities registered a high of $8.6 million during FY2020, and its lowest value of $6.7 million during FY2024.
  • Over the past 3 years, Amphastar Pharmaceuticals' median Gains from Investment Securities value was $7.8 million (recorded in 2023), while the average stood at $7.4 million.
  • Data for Amphastar Pharmaceuticals' Gains from Investment Securities shows a maximum YoY fell of 14.26% (in 2024) over the last 5 years.
  • Over the past 5 years, Amphastar Pharmaceuticals' Gains from Investment Securities (Yearly) stood at $8.6 million in 2020, then decreased by 1.45% to $8.5 million in 2021, then declined by 6.23% to $7.9 million in 2022, then dropped by 2.10% to $7.8 million in 2023, then fell by 14.26% to $6.7 million in 2024.